Nov. 11, 2025 Japanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimer’s, does not improve the brain’s waste clearance system in the short term. This implies that nerve damage ...

More than a century ago, Alois Alzheimer noted unusual changes in brain fats, which he described as "lipoid granules," along with the buildup of amyloid‐beta (amyloid) plaques and tau protein tangles.